Institute for International Research

Hear leading experts reveal recent advancements and clinical data of antibody alternatives and next generation technologies

Scientific Advisory Committee: Andrew Bradbury, M.B., B.S., Ph.D., Research Scientist, Los Alamos National Laboratories Bipin K. Dalmia, Ph.D., MBA, Vice President, Biolex Therapeutics Dimiter S. Dimitrov, Ph.D., ScD, Senior Investigator, Protein Interactions, CCRNP, CCR, NCI-Frederick Larry Gold, Ph.D., CEO & Chairman of the Board, SomaLogic, Inc. Paul Watt, Ph.D., Vice President, Drug Discovery, Phylogica Ltd Pre-Conference Workshop Enabling Technologies for Advancing Biologics Toward the Clinic Brian Miller, Ph.D., Sr. Scientist, Molecular Engineering, Biogen Idec, Inc. Gregory Weiss, Ph.D., Associate Professor, U.C. Irvine William J. Boyle, Ph.D., President and Chief Science Officer, Anaptys Biosciences, Inc. Ralph Minter, Ph.D., Head of Technology, Research, MedImmune Marty Stanton, Ph.D., Chief Scientific Officer, SomaLogic Michael D. Smith, Ph.D., Field Scientist, Sidec Inc. Panel Discussion Strategies and Drivers of Mergers & Acquisitions in the Antibody Alternative Space Moderators: Larry Gold, Ph.D., CEO & Chairman of the Board, SomoLogic Beth Jacobs, Partner, Bio IB Panelists: Eric Furfine, Ph.D., Sr. VP, Research & Preclinical Development, Adnexus, a Bristol-Myers Squibb R&D Co. Ruud de Wildt Ph.D., Manager, Biopharm CEDD, GSK-Domantis Group Chuck Wilson Ph.D., VP Alliance Management, Technology, Archemix

Keynote Address

The Good, The Bad, and The Ugly: Drivers for Development of Antibody Alternatives
Peter J. Hudson, Ph.D., Research Director, (Neurosciences and Molecular Imaging), CSIRO; Co-chair, HUPO-HAI and SAB Chair, AviPep Pty Ltd.

The 'beyond antibodies' field has matured into an industry in which there are multiple examples of protein scaffolds and domain antibodies in the clinic. There continues to be a rise in acquisitions within this market which only emphasizes the value of these technologies.

IBC's third annual Beyond Antibodies conference is the industry's only event to focus exclusively on alternatives to antibody technology. Next generation antibody and protein scaffolds are continually being developed and rapid advancements have been made in this highly emerging field. The development of these technologies is to overcome the limitations of traditional antibody technology and reduce the time of drug discovery. This year's conference will cover the recent advancements and scientific benefits, as well as business perspectives driving much of the M & A activity.

Attend this conference and you will:

• Learn the latest scientific advancements in this rapidly developing field
• Review data from leading organizations who have antibody alternatives in the clinic or approaching the clinic
• Participate in a business discussion with industry leaders and find out what the characteristics are for companies that have been acquired or may be acquired
• Explore technologies that enable the advancement of biologics toward the clinic
• Gain insight into the unique advantages of various delivery methods
• Hear an in-depth comprehensive regulatory view on immunogenicity
• Listen to how companies are improving pharmacokinetics